January 4, 2018
Announcement no. 1
Today, BioPorto has been informed that Board member Niels Christian Nielsen will not be seeking re-election at BioPorto’s Annual General Meeting on April 13, 2018.
Thomas Magnussen says: “Niels Christian has made his decision on the background of a substantial expansion of his important activities connected with the creation of the World Refugee School, a global initiative established by a group of leading technology, education, and international development companies. We have been very fortunate to have Niels Christian on the Board of Directors in BioPorto, and Niels Christian has provided extremely valuable support to the company during his tenure. We wish Niels Christian the best of luck in his future endeavours. As part of its ordinary annual review of the composition of the Board of Directors, BioPorto’s Nomination Committee is evaluating new candidates for the Board of Directors.”
For further information, please contact:
Thomas Magnussen, Chairman of the Board of Directors
Telephone +45 4529 0000, e-mail investor@bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
To subscribe or unsubscribe to news mails from BioPorto (Announcements, newsletters and other news), please send an e-mail to investor@bioporto.com.
http://prlibrary-eu.nasdaq.com/Resource/Download/3a394d73-fadb-4f7d-b531-1a83bbb40564
